← All trials
NCT04264598
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 21, 2017
- Primary completion
- Dec 19, 2017
- Completion date
- Dec 28, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaOverall official - principal investigator
- Beijing Minhai Biotechnology Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.